A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache

Eli Lilly and Company0 个研究点目标入组 109 人开始时间: 2015年4月24日最近更新: 2018年8月20日

适应症

试验速览

暂无简介。

•Participants (or patients) with a history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of =1 month.
•Participants (or patients) are able to distinguish cluster headache attacks from other headaches
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 157
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device.
•Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).
•Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia
•A history of migraine variants that could implicate or could be confused with ischemia
•Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins
•A history or presence of other medical illness that indicates a medical problem that would preclude study participation.
•Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.
•Women who are pregnant or nursing.

发起方